Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

A Phase I/II Study to Investigate the Addition of Venetoclax to Dasatinib and Steroids in Patients with Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): The Venda Trial, in Progress

Jessica T. Leonard, Rachel Cook, Laura F. Newell, Arpita Gandhi, Ronan T. Swords, Christopher A. Eide, Brandon Hayes-Lattin, Kara Johnson, Elie Traer, Stephen E. Kurtz, Jennifer N. Saultz, Cristina Tognon, Jeffrey W Tyner, Curtis A. Lachowiez

Blood (2023) 142 (Supplement 1): 1512.

https://doi.org/10.1182/blood-2023-188313

Published: 2023

Journal Articles

Prognostic Significance of NCAM1 (CD56) Expression in AML Patients Treated with HMA+Venetoclax

Blood (2023) 142 (Supplement 1): 5762.

https://doi.org/10.1182/blood-2023-188311

Published: 2023

Journal Articles

Results of a Phase 1 Trial Testing the Novel Combination Therapy of Venetoclax and Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Patients

Blood (2023) 142 (Supplement 1): 1515.

https://doi.org/10.1182/blood-2023-191166

Published: 2023

Journal Articles

Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML

Blood (2023) 142 (Supplement 1): 978.

https://doi.org/10.1182/blood-2023-179527

Published: 2023

Journal Articles

Cebpβ/IL1/TNFα Positive Feedback Loop Drives Drug Resistance of BCL2 and MDM2 Inhibitors in Monocytic Leukemia Cells

Basil Allen, Daniel Bottomly, Anthony Wang, Thomas Koehnke, Lindsey Savoy, Peter Ryabini, Reid Chen, Kara Johnson, Stephen E. Kurtz, Anupriya Agarwal, Michelle Barton, Brian J. Druker, Ravi Majeti, Jeffrey W Tyner, Shannon K McWeeney, Haijiao Zhang

Blood (2023) 142 (Supplement 1): 2937.

https://doi.org/10.1182/blood-2023-178096

Published: 2023

Journal Articles

Computational Approach Based on Independent Drug Action Identifies Clinically Relevant Combinations for Acute Myeloid Leukemia

Xiao Xian Lin, Vedant Sandhu, Christopher A. Eide, Stephen E. Kurtz, Disha Malani, Tom Erkers, Olli Kallioniemi, Jeffrey W Tyner, Shruti Bhatt

Blood (2023) 142 (Supplement 1): 5015.

https://doi.org/10.1182/blood-2023-188731

Published: 2023

Journal Articles

A Rapid Test to Evaluate the Tumor Differentiation State of Acute Myeloid Leukemias

Stephen E. Kurtz, Christopher A. Eide, Nicola Long, Daniel Bottomly, Shannon K McWeeney, Akosha Taylor, Brian J. Druker, Sudarshan Anand, Curtis A. Lachowiez, Jeffrey W Tyner

Blood (2023) 142 (Supplement 1): 3643.

https://doi.org/10.1182/blood-2023-180105

Published: 2023

Journal Articles

Targeting Sumoylation with Subasumstat (TAK-981), a Selective Inhibitor of SUMO-Activating Enzyme (SAE), Induces Mitochondrial Dysfunction in Preclinical Models of Non-Hodgkin Lymphoma (NHL)

Tingting Liu, Vi Lam, Elana Thieme, Olga Danilova, Nur Bruss, Lapo Alinari, Jeffrey W. Tyner, Stephen E. Kurtz, Zheng Xia, Alexey V Danilov

Blood (2022) 140 (Supplement 1): 6016–6017.

https://doi.org/10.1182/blood-2022-159691

Published: 2022

Journal Articles

The Aryl Hydrocarbon Receptor Defines a Unique Genomic and Immune Signature in AML Characterized By Monocytic Differentiation, Venetoclax Resistance and Is Targetable By Ahr Antagonist

Jennifer N. Saultz, Daniel Bottomly, Faith Burns, Kaelan Byrd, Yoko Kosaka, Shannon K. McWeeney, Stephen E. Kurtz, Guang Fan, Andy Kaempf, Karen McGovern, Lei Wang, Marta Sanchez-Martin, Dan S Kaufman, Evan F. Lind, Jeffrey W. Tyner

Blood (2022) 140 (Supplement 1): 3071–3072.

https://doi.org/10.1182/blood-2022-163166

Published: 2022

Journal Articles

Defining Clinical and Molecular Biomarkers for Venetoclax-Based Drug Combinations to Augment AML Therapy

Christopher A. Eide, Stephen E. Kurtz, Andy Kaempf, Nicola Long, Sunil K Joshi, Tamilla Nechiporuk, Ariane Huang, Charles Dibb, Daniel Bottomly, Shannon K. McWeeney, Bill H. Chang, Brian J. Druker, Jeffrey W. Tyner

Blood (2022) 140 (Supplement 1): 1025–1027.

https://doi.org/10.1182/blood-2022-159264

Published: 2022

Journal Articles

Novel Combination Therapy of Venetoclax and Ruxolitinib in the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia

Uma Borate, Jennifer N. Saultz, Andy Kaempf, Jessica Minnier, Cristina E. Tognon, Stephen E. Kurtz, Christopher A. Eide, Prapti A. Patel, Yazan F. Madanat, Peter Clement, Sammantha Avaylon, Shikha Misra, Brian J. Druker, Jeffrey W. Tyner

Blood (2021) 138 (Supplement 1): 2333.

https://doi.org/10.1182/blood-2021-152903

Published: 2021

Journal Articles

Associating Ex Vivo Drug Sensitivity with Differentiation Status Identifies Effective Drug Combinations for Acute Myeloid Leukemia

Christopher A. Eide, Stephen E. Kurtz, Andy Kaempf, Nicola Long, Daniel Bottomly, Olga Nikolova, Brian J. Druker, Shannon K. McWeeney, Jeffrey W. Tyner, Anupriya Agarwal

Blood (2021) 138 (Supplement 1): 1301.

https://doi.org/10.1182/blood-2021-152043

Published: 2021

Journal Articles

Pharmacologic Inhibition of B Cell-Receptor-Associated Kinases with CG-806 Induces Apoptosis and Metabolic Reprogramming in Aggressive Non-Hodgkin Lymphoma (NHL) Models

Elana Thieme, Vi Lam, Nur Bruss, BS, Fei Xu, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Alexey Danilov, MD, Tingting Liu

Blood (2020) 136 (Supplement 1): 29.

https://doi.org/10.1182/blood-2020-134957

Published: 2020

Journal Articles

Pharmacologic Targeting MCL1 with AZD5991 Induces Apoptosis and Mitochondrial Dysfunction in Non-Hodgkin Lymphoma (NHL) Cells

Tingting Liu, Fei Xu, Elana Thieme, Vi Lam, Guang Fan, MD PhD, Liana Nikolaenko, MD, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Olga Danilova, Alexey Danilov, MD

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-134951

Published: 2020

Journal Articles

Patterns of Venetoclax Sensitivity in Chronic Lymphocytic Leukemia

James T Dibb, DO, Nicola Long, Christopher A. Eide, Stephen E Kurtz, PhD, Cristina E. Tognon, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD

Blood (2020) 136 (Supplement 1): 12–14.

https://doi.org/10.1182/blood-2020-137674

Published: 2020

Journal Articles

A Functional Profiling of Microenvironmental Factors and Small Molecules Reveals Monocyte Chemoattractant Protein-1 Mediates Drug Resistance in Acute Myeloid Leukemia

Rucha V Modak, PhD, Sara J Gosline, Alisa Damnernsawad, PhD, Tamilla Nechiporuk, PhD, Ted Laderas, PhD, Guanming Wu, PhD, Paul Piehowski, Paul.Piehowski@pnnl.gov, Stephen E Kurtz, PhD, Christopher A. Eide, Jeffrey W. Tyner, PhD, Karin Rodland, rodland@ohsu.edu, Shannon K. McWeeney, PhD, Anupriya Agarwal, PhD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-141686

Published: 2020

Journal Articles

Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia

Christopher A. Eide, Stephen E Kurtz, PhD, Andy Kaempf, MS, Nicola Long, Jessica Leonard, MD, Bill H. Chang, MD PhD, Motomi Mori, PhD, Brian J. Druker, Jeffrey W. Tyner

Blood (2019) 134 (Supplement_1): 3950.

https://doi.org/10.1182/blood-2019-131288

Published: 2019

Journal Articles

Genome-Wide CRISPR Screening Identifies MAPK and Mtorc Pathways As Regulators of Sorafenib Resistance in Acute Myeloid Leukemia

Alisa Damnernsawad, PhD, Tamilla Nechiporuk, PhD, Daniel Bottomly, MS, Stephen E Kurtz, PhD, Christopher A. Eide, Shannon K. McWeeney, PhD, Jeffrey W. Tyner

Blood (2019) 134 (Supplement_1): 2557.

https://doi.org/10.1182/blood-2019-128877

Published: 2019

Journal Articles

Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia

Stephen E Kurtz, PhD, Christopher A. Eide, Andy Kaempf, MS, Nicola Long, Anupriya Agarwal, PhD, Cristina E. Tognon, Motomi Mori, PhD, Brian J. Druker, Jeffrey W. Tyner

Blood (2019) 134 (Supplement_1): 878.

https://doi.org/10.1182/blood-2019-126020

Published: 2019

Journal Articles

Genome-Wide CRISPR Screening in Acute Myeloid Leukemia Cells Identifies Genes in the PI3K/AKT/mTOR and MEK/ERK Pathways That Define Sensitivity to Trametinib

Tamilla Nechiporuk, PhD, Alisa Damnernsawad, PhD, Daniel Bottomly, MS, Quinlan Morrow, BS, Suyoun Choi, Sofia Beer, Stephen E Kurtz, PhD, Shannon K. McWeeney, PhD, Jeffrey W. Tyner

Blood (2019) 134 (Supplement_1): 1395.

https://doi.org/10.1182/blood-2019-129117

Published: 2019

NARROW

A Phase I/II Study to Investigate the Addition of Venetoclax to Dasatinib and Steroids in Patients with Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): The Venda Trial, in Progress

Prognostic Significance of NCAM1 (CD56) Expression in AML Patients Treated with HMA+Venetoclax

Results of a Phase 1 Trial Testing the Novel Combination Therapy of Venetoclax and Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Patients

Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML

Cebpβ/IL1/TNFα Positive Feedback Loop Drives Drug Resistance of BCL2 and MDM2 Inhibitors in Monocytic Leukemia Cells

Computational Approach Based on Independent Drug Action Identifies Clinically Relevant Combinations for Acute Myeloid Leukemia

A Rapid Test to Evaluate the Tumor Differentiation State of Acute Myeloid Leukemias

Targeting Sumoylation with Subasumstat (TAK-981), a Selective Inhibitor of SUMO-Activating Enzyme (SAE), Induces Mitochondrial Dysfunction in Preclinical Models of Non-Hodgkin Lymphoma (NHL)

The Aryl Hydrocarbon Receptor Defines a Unique Genomic and Immune Signature in AML Characterized By Monocytic Differentiation, Venetoclax Resistance and Is Targetable By Ahr Antagonist

Defining Clinical and Molecular Biomarkers for Venetoclax-Based Drug Combinations to Augment AML Therapy

Novel Combination Therapy of Venetoclax and Ruxolitinib in the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia

Associating Ex Vivo Drug Sensitivity with Differentiation Status Identifies Effective Drug Combinations for Acute Myeloid Leukemia

Pharmacologic Inhibition of B Cell-Receptor-Associated Kinases with CG-806 Induces Apoptosis and Metabolic Reprogramming in Aggressive Non-Hodgkin Lymphoma (NHL) Models

Pharmacologic Targeting MCL1 with AZD5991 Induces Apoptosis and Mitochondrial Dysfunction in Non-Hodgkin Lymphoma (NHL) Cells

Patterns of Venetoclax Sensitivity in Chronic Lymphocytic Leukemia

A Functional Profiling of Microenvironmental Factors and Small Molecules Reveals Monocyte Chemoattractant Protein-1 Mediates Drug Resistance in Acute Myeloid Leukemia

Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia

Genome-Wide CRISPR Screening Identifies MAPK and Mtorc Pathways As Regulators of Sorafenib Resistance in Acute Myeloid Leukemia

Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia

Genome-Wide CRISPR Screening in Acute Myeloid Leukemia Cells Identifies Genes in the PI3K/AKT/mTOR and MEK/ERK Pathways That Define Sensitivity to Trametinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only